Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

In this cohort study, the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) semaglutide and tirzepatide was associated with a lower risk of dementia, stroke, and all-cause mortality in ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...